KBC Group’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

KBC Group’s Portfolio EIGR Stock Details EIGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-520	Closed	-$104K	–	1346
2021 Q3	$104K	Hold	520	–	–	﹤0.01%	1156
2021 Q2	$133K	Buy	520 +243	+88%	+$60.6K	﹤0.01%	1137
2021 Q1	$73K	Hold	277	–	–	﹤0.01%	1216
2020 Q4	$102K	Hold	277	–	–	﹤0.01%	1159
2020 Q3	$68K	Hold	277	–	–	﹤0.01%	1158
2020 Q2	$80K	Buy	277 +54	+24%	+$15.9K	﹤0.01%	1177
2020 Q1	$46K	Hold	223	–	–	﹤0.01%	1207
2019 Q4	$100K	Sell	223 -119	-35%	-$42.2K	﹤0.01%	1356
2019 Q3	$105K	Buy	+342	New	+$111K	﹤0.01%	1330

Other funds holding EIGR

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

IVM

InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

PAWC

P.A.W. Capital Greenwich, Connecticut $131M AUM 35.16% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

KBC Group's EIGR Position: Q4 2021 in Review

KBC Group sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q4 2021, closing a stake of 520 shares — an estimated $104K sold.

KBC Group first reported a position in EIGR in Q3 2019 and held it in 9 quarters. The position peaked at $133K in Q2 2021. 85 funds tracked by Wall St. Rank hold EIGR as of Q4 2021.

KBC Group reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q4 2021 after selling out during the quarter.
KBC Group sold 520 Eiger BioPharmaceuticals, Inc. shares in Q4 2021, an estimated $104K.
KBC Group first reported a position in Eiger BioPharmaceuticals, Inc. in Q3 2019 and held it in 9 quarters.
KBC Group's Eiger BioPharmaceuticals, Inc. position peaked at $133K in Q2 2021.
85 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q4 2021.

Based on KBC Group's 13F filing for Q4 2021, filed 3 Feb 2022.